160 Health International Limited
健 康 160 国 际 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2656)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

The board (the "**Board**") of directors (the "**Directors**") of 160 Health International Limited (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") is pleased to announce the unaudited interim results of the Group for the six months ended June 30, 2026 (the "**Reporting Period**"), together with the comparative figures for the corresponding period in 2025, which shall be read in conjunction with the management discussion and analysis, as follows:

FINANCIAL HIGHLIGHTS

	Six months ended June 30,		
	2026	2025	Change
	RMB'000	*RMB'000*	*%*
	Unaudited	Unaudited	
Revenue	**318,750**	290,664	9.7
Gross profit	**85,372**	64,036	33.3
Operating profit/(loss)	**5,534**	(18,012)	130.7(2)
Profit/(loss) for the period	**1,676**	(19,625)	108.5(2)
Adjusted net profit/(loss) (non-IFRS measure)(1)	**5,452**	(5,061)	207.7(2)

	Six months ended June 30,		
	2026	2025	Change
	RMB'000	*RMB'000*	*%*
	Unaudited	Unaudited	
Revenue by product or service type			
Sale of pharmaceutical and healthcare products	**217,637**	211,405	2.9
Digital healthcare and wellness solutions	**101,113**	79,259	27.6

Notes:

(1) We define "adjusted net profit/(loss) (non-IFRS measure)" as profit/(loss) for the period and adding back (1) share-based compensation expenses and (2) listing expenses.

(2) Since operating profit, profit for the period and adjusted net profit (non-IFRS measure) were recorded for the six months ended June 30, 2026, compared to operating loss, loss for the period and adjusted net loss (non-IFRS measure) recorded for the six months ended June 30, 2025, the percentage changes are not comparable.

MANAGEMENT DISCUSSION AND ANALYSIS

Through our platform, we had extended our service outreach to over 260 cities across China as of June 30, 2026. As of June 30, 2026, our platform had connected with over 45,141 medical and healthcare institutions, representing a year-on-year increase of 1.01%, which comprised over 14,658 hospitals (including 3,549 Class III hospitals) and over 30,483 primary healthcare institutions. As of the same date, among our collaborating medical and healthcare institutions, there were over 6,900 private institutions primarily providing consumer healthcare services on our platform, such as dental, ophthalmology, and physical examination services. In addition, we had established cooperative relationships with over 908,300 medical professionals, which included approximately 48,400 registered physicians. Concurrently, our platform boasts a substantial user base, with 61.9 million registered individual users as of June 30, 2026, marking a year-on-year increase of 8.69%, and our platform recorded average MAUs of 3.4 million for the Reporting Period.

BUSINESS REVIEW

We are an experienced pharmaceutical and healthcare product seller and a leading digital healthcare integrated service provider in China. We offer a wide assortment of high-quality pharmaceutical and healthcare products under the pharmaceutical sale model, to address a spectrum of customer needs. In addition, through our online healthcare and wellness service platform, Healthcare 160 Platform, we provide digital healthcare and wellness solutions, empowering each platform participant, primarily including business customers, medical and healthcare institutions, medical professionals, individual users, and third-party merchants, throughout the healthcare value chain and driving the digital transformation of China's healthcare and wellness industry. At the same time, through the innovative launch of the "160AI Hospital" operational collaboration business model, we assist in promoting the upgrade of hospitals' online portals from basic registration tools to patient operation and wellness service conversion platforms.

During the Reporting Period, we focused on two major directions — AI service capabilities and internal efficiency upgrade — laying a solid foundation for the vertical penetration and horizontal expansion of the Company's business. In terms of AI service capabilities, we completed the systematic establishment of core AI diagnostic capabilities constrained by medical knowledge graphs, achieving breakthroughs in both consultation and diagnostic modules. Through structured guidance, we helped users clearly articulate their chief complaints and recommended appropriate medical institutions based on user symptoms. Meanwhile, we have built medical safety red-line compliance mechanisms into the AI diagnostic module to ensure the safety and compliance of AI diagnostics across multiple implementation scenarios, including intelligent triage, pre-consultation, and intelligent follow-up, providing a core engine for building differentiated intelligent healthcare and wellness service experiences going forward. In terms of internal efficiency upgrade, we completed end-to-end AI-driven delivery from requirements to testing through AI Coding, accumulating a set of reusable methodologies that effectively improved research and development efficiency and technical response capabilities. At the same time, by piloting AI-based digital workforce across various departments, we effectively enhanced operational efficiency, creating a solid foundation for the future large-scale delivery of requirements.

Our business consists of two major segments, namely (i) sale of pharmaceutical and healthcare products and (ii) digital healthcare and wellness solutions. In particular, the sale of pharmaceutical and healthcare products represents our main revenue stream, providing a solid foundation for our overall growth. Our digital healthcare and wellness solutions serve as a strategic focus and key driver of revenue, acting as the central force behind our future growth and the enhancement of our comprehensive service capabilities. The synergy between these two segments creates a unique competitive advantage, positioning us as a pharmaceutical and healthcare product seller and a digital healthcare integrated service provider in China. During the Reporting Period, our total revenue amounted to RMB318.8 million, representing a year-on-year increase of 9.7%.

(i) Sale of Pharmaceutical and Healthcare Products

Our pharmaceutical and healthcare product sales business is an indispensable component of our closed-loop digital healthcare and wellness services. We have established a strong collaborative network with pharmaceutical companies, distributors, and various suppliers. Leveraging our robust supply chain system and extensive supply network, we selectively procure a diverse range of high-quality pharmaceutical and healthcare products from pharmaceutical companies, distributors, and various suppliers. We have developed a diversified product matrix covering pharmaceuticals, medical devices, and daily healthcare products. Through our integrated online and offline channels, we provide business customers and individual users with high-quality, efficient, and competitively priced products and supply services.

Drawing on our deep industry expertise, professional product selection capabilities, and precise market insights, we continuously optimize our product mix and supply efficiency and enhance supply chain stability and service capacity. During the Reporting Period, we upgraded several specialized pharmaceutical warehouses and continued to advance the development of our digital supply chain for pharmaceutical and healthcare products. By completing the upgrade of our intelligent ERP system, we conducted real-time inventory monitoring and periodic analysis of business customer needs client demand, enabling intelligent procurement decision-making to further satisfy the specific needs of business customers, provide a stable and reliable supply of pharmaceutical and healthcare products for individual users, and provide robust support for the efficient operation of the Company's overall healthcare ecosystem.

During the Reporting Period, revenue from the sale of pharmaceutical and healthcare products amounted to RMB217.6 million, representing a year-on-year increase of 2.9%.

(ii) Digital Healthcare and Wellness Solutions

Our digital healthcare and wellness solutions cover three business segments, primarily comprising (1) online marketing solutions for medical and healthcare institutions and third-party merchants; (2) digital hospital solutions for medical and healthcare institutions; and (3) online healthcare services for individual users. Additionally, we also offer certain value-added ad hoc services to our customers, such as technical services for system development, most of which are one-off in nature.

➢ ***Online Marketing Solutions***

Collaboration with medical and healthcare institutions is central to our business. We drive the digital transformation of these institutions through our solutions, which are designed to create an open-system architecture that seamlessly integrates the internet with healthcare and wellness services, delivering a more efficient, precise, and intelligent patient experience. To enhance the operational efficiency of our platform, we have built upon our existing 160 Cloud Hospital to create 160AI Hospital through the deep integration of AI applications. We also offer platform management solutions to medical and healthcare institutions via our two proprietary back-end management software, namely Jiuyitong and 160AI Hospital. By leveraging our solutions, institutions can achieve higher efficiency while effectively monitoring their operations on our platform and enhancing their online brand visibility.

Through our platform, these institutions can leverage multi-channel, high-precision marketing strategies to drive patient growth and enhance patient engagement. Promotional methods include advertising, publishing popular science articles on medicine, and executing strategic marketing campaigns. Furthermore, our platform enables medical and healthcare institutions to overcome spatial limitations and achieve broader, more effective user outreach.

We actively promote the strategic integration of artificial intelligence technology and digital healthcare and wellness services, capturing development opportunities within the digital healthcare integrated service industry. In 2025, we officially launched the AI Hospital holistic solution, which integrates artificial intelligence throughout the entire process from pre-diagnosis, diagnosis and post-diagnosis to health management via intelligent tools including "AI Operational Assistant", "AI Doctor Assistant", and "AI Health Steward". These tools bridge the gaps between hospitals, doctors, and patients. The 160AI Hospital holistic solution has been applied in medical scenarios such as patient stratification and labeling, outpatient guidance, pre-consultation, patient accompaniment, and health management, driving a comprehensive upgrade of medical services toward precision and intelligence.

Using the registration services on hospital WeChat official accounts as an entry point, the "160AI Hospital" operational collaboration business model comprehensively optimizes the online medical experience for patients and strengthens hospitals' operational management capabilities. While improving the quality of medical services, it effectively helps partner hospitals control operating costs, enhance patient satisfaction, and optimize revenue structure. As of June 30, 2026, the cumulative number of public medical institutions with which we have entered into operational collaboration reached 163, including 78 Class IIIA hospitals, accounting for approximately 47.9%, and a total of 120 Class III or above hospitals, accounting for approximately 73.6%. During the Reporting Period, the "160AI Hospital" operational collaboration business model was market-validated and achieved commercialization, beginning to contribute revenue to us.

➢ ***Digital Hospital Solutions***

We provide digital hospital solutions to medical and healthcare institutions, including intelligent in-hospital disease prevention and management, as well as the development and upgrading of in-hospital information systems. Our solutions enable medical institutions to optimize the allocation of medical resources, improve responsiveness to patient needs, and enhance the quality of diagnosis and treatment. This results in cost reduction and efficiency enhancement across the entire spectrum of healthcare and wellness services.

We have continued to strengthen our presence in the in-hospital business sector and advance product innovation. Through the "Blue Spirit Infection Control GPT" (藍靈感控GPT), our autonomous risk management AI large model specifically designed for medical quality and safety management, we use hospital infection prevention and control as the core application scenario to facilitate full-cycle risk management from risk profile generation and automated intervention mechanisms to dynamic clinical supervision and feedback for optimization. By efficiently processing vast amounts of hospital data, it prevents infections at source and shifts the focus of infection control to an earlier stage. This supports the standardization and refinement of medical quality control, delivering safer and more precise medical services to patients. In addition, we continue to expand the application boundaries of the "Blue Spirit Infection Control GPT", actively exploring its deployment across diverse medical scenarios such as clinical decision support and medical data governance, and continuously empowering the digital and intelligent transformation of medical and healthcare institutions through intelligent technology.

- ***Online Healthcare Services***

  We are dedicated to delivering trusted, affordable, professional, and convenient online healthcare services to individual users through collaboration with medical and healthcare institutions and medical professionals. Our one-stop platform offers online registration, consultations, consumer healthcare packages, and pharmaceutical and healthcare products. We have integrated renowned medical and healthcare institutions across various specialties into our platform, enabling individual users to easily book appointments and consult with highly-regarded medical professionals. We continuously expand our online healthcare services, currently covering both critical medical care and consumer healthcare sectors to meet the evolving needs of our users.

- ***Others***

  To a lesser extent, we provide certain value-added ad hoc services to customers, such as technical services for system development and individual membership services. Except for individual membership services, these services are non-recurring in nature and are primarily aimed at addressing specific customer needs in conjunction with the implementation of our other solutions.

For the Reporting Period, revenue from digital healthcare and wellness solutions amounted to RMB101.1 million, representing a year-on-year growth of 27.6%. Its contribution to our total revenue increased from 27.3% for the six months ended June 30, 2025 to 31.7% for the six months ended June 30, 2026.

OUTLOOK

As a pharmaceutical and healthcare product seller and a leading digital healthcare and wellness service platform in China, we are committed to offering a wide range of pharmaceutical and healthcare products as well as well-rounded digital healthcare and wellness solutions in the highly competitive and rapidly growing Chinese market. Moving forward, we plan to proactively explore and expand international business, targeting the global market. At the strategic level, we consistently embrace long-termism, driving business growth through technological innovation and continuing to deepen the integration of AI technology with medical and healthcare scenarios.

Regarding the sale of pharmaceutical and healthcare products, we will move towards the goal of building an open and connected industrial internet platform, further iterating and optimizing our intelligent ERP system to promote online sales services. By establishing an independent warehouse and upgrading our one-stop procurement service platform, we will create a fully integrated internet closed-loop process from "online demand submission and intelligent supply matching to logistics tracking and offline fulfillment", significantly enhancing procurement efficiency and service responsiveness for business customers. In addition, we will systematically promote the exploratory integration of AI diagnostic and treatment plans with offline medical services, enrich the service matrix of the Group's sales of pharmaceutical and healthcare products, and further consolidate the user base and scenario coverage of the Group's platform.

Regarding digital healthcare and wellness solutions, we will continue to optimize our existing business structure, continue to deepen the nationwide layout of the "160AI Hospital" operational collaboration model, take hospitals at all levels as the core direction of expansion, continuously expand the coverage of our network of collaborating medical institutions, and iterate and upgrade the core product system of the 160AI Hospital solution. Meanwhile, we plan to accelerate the intelligent iteration of patient health management capabilities. With the user's explicit authorization, we automatically collect and collate user health records, desensitize and utilize the relevant data. Whilst safeguarding user data privacy and security through measures such as access control, we achieve seamless connection with in-hospital information systems and synchronously generate health education and humanistic care content, thereby building an end-to-end capability framework of "risk perception, intelligent triage, data closed loop, and humanistic support" in the actual operation of AI hospitals. Furthermore, we will promote the deep application of AI technology in key links of medical services, actively explore commercial models for exporting AI service capabilities to medical and healthcare institutions, and integrate industry resources to introduce high-quality specialized service providers, thereby expanding multi-dimensional service scenarios, broadening our commercial boundaries, building a comprehensive healthcare service system, and continuously consolidating the Company's core competitive edge in the digital healthcare and wellness field.

While advancing the aforementioned businesses, we have also noted significant industry opportunities in the computing power sector. According to disclosures at the press conference of the State Council Information Office on March 24, 2026, the daily average Token calls in China were 100 billion at the start of 2024, and exceeded 140 trillion by March 2026, fully demonstrating that AI development in China has entered a stage of rapid growth, with application scenarios continuously deepening. Currently, the integration of AI and the healthcare and wellness industry is moving deeper from workflow assistance into core stages such as clinical decision-making and health management. The Group is deeply rooted in the internet healthcare and wellness industry, fully understands the practical needs of medical and healthcare institutions and industry participants for AI infrastructure, and deploys integrated AI healthcare and wellness solutions as a natural extension to respond to evolving client demands and implement the Company's development strategy. While deploying AI product applications for clients, we noticed widespread demand among clients for supporting server hardware. To this end, in collaboration with server suppliers, we plan to take the integrated solution of "healthcare AI agent + hardware + integrated debugging service" as the current business entry point to provide clients with overall delivery services pairing AI healthcare products with hardware infrastructure, meeting clients' comprehensive needs in a one-stop manner. As the business matures and client demand deepens, we will gradually extend to the deployment and servicing of medical domain-specific large language models, and on this basis actively explore the possibilities of a Token sales business model, establishing a progressive development path from infrastructure to platform operation. The Group believes that the orderly rollout of this business can form good synergies with existing businesses, continuously reinforce our core competitive advantages in the AI healthcare and wellness track, and is expected to become our second growth curve for revenue.

In the future, the Group plans to increase our research and development investment in artificial intelligence, focusing on scenarios of frequent occurrence and with inelastic demand in the healthcare industry. We will promote products and services based on multi-agent collaboration, deeply applying them across core operational links including patient-doctor group management, evidence-based medicine-assisted decision-making, intelligent medical insurance calculation, departmental ledger management, and operation of high-value health services. Through technology implementation and scenario integration, the Group will continuously refine and improve our professional and intelligent "Medical Digital Staff" system, driving business model upgrades and allowing data and operations to replace mere service empowerment as the core driving force for value creation. Through the in-depth implementation of AI technology, medical staff will be relieved from highly repetitive, low-value tasks, allowing them to focus on high-value clinical decision-making and patient care, continuously improving the quality of medical services and medical safety. On this basis, we will assist collaborating medical and healthcare institutions in breaking through the short-chain service boundaries of one-time consultations, establishing long-term health management relationships covering users' entire lifecycle, thereby constructing our sustainable and profitable business model.

At the same time, we actively advance our international expansion, focusing on high-potential overseas markets and deeply cultivating the Southeast Asian region to steadily implement our international strategy. At the product level, our full patient-end product matrix now supports multi-language versions including Simplified Chinese, Traditional Chinese, English, and Japanese, enabling rapid alignment with user needs across multiple regions. Building upon a mature product foundation and industry accumulation, we have initiated medical resource matching for the Southeast Asian healthcare market. Going forward, through close cooperation and operational deployment with prominent local medical and healthcare institutions, we will establish the foundation for our overseas business services. In the future, we will continuously follow global digital healthcare industry trends, adhere to the principles of prudence, pragmatism, and steady implementation, methodically advance our business layout in Southeast Asia, gradually achieve scale breakthroughs in international operations, and inject new momentum into the Group's long-term growth.

In the long term, with continuous technological advancements and the expansion of application scenarios, the use of AI in the medical field will deepen and broaden further. It is expected to play a more significant role in primary healthcare services, chronic disease management, and preventive care, serving as a pivotal force to alleviate the uneven distribution of medical resources and improve national health levels, injecting new momentum into industry development. We will also combine existing business scenarios with client demand to methodically advance resource integration and deployment. We will expand the integrated "healthcare AI agent + hardware + integrated debugging service" solution to more clients and explore further implementation pathways for computing power services in the digital healthcare and wellness services sector. Building on this foundation, we will steadily advance our strategic initiatives, moving toward our vision of becoming a "world-leading internet medical and healthcare platform". We are committed to achieving the leap from being a "comprehensive digital medical and healthcare service platform" to becoming a "medical AI intelligent ecosystem infrastructure and service provider".

FINANCIAL REVIEW

REVENUE

The Group's revenue increased by 9.7% from approximately RMB290.7 million for the six months ended June 30, 2025 to approximately RMB318.8 million for the six months ended June 30, 2026. Such increase was primarily driven by the strong performance of our digital healthcare and wellness solutions business.

Revenue from sale of pharmaceutical and healthcare products increased by 2.9% from approximately RMB211.4 million for the six months ended June 30, 2025 to approximately RMB217.6 million for the six months ended June 30, 2026, primarily due to the advancement of digital supply chain development for pharmaceutical and healthcare products, which further satisfied business customer needs and promoted steady growth in the wholesale business.

Revenue from digital healthcare and wellness solutions increased by 27.6% from approximately RMB79.3 million for the six months ended June 30, 2025 to approximately RMB101.1 million for the six months ended June 30, 2026, primarily due to the significant market competitiveness of our "160AI Hospital" product, together with the rapid growth in the number of public hospitals collaborating under the "160AI Hospital" operational collaboration business model, which drove a steady increase in the number of paying collaborating medical and healthcare institutions and a rapid growth in revenue from online marketing solutions.

COST OF SALES

The Group's cost of sales increased by 3.0% from approximately RMB226.6 million for the six months ended June 30, 2025 to approximately RMB233.4 million for the six months ended June 30, 2026. Specifically, the cost of sales for pharmaceutical and healthcare products increased by 2.5%, while the cost of sales for digital healthcare and wellness solutions increased by 8.9%. It was primarily attributable to the rapid growth in revenue from digital healthcare and wellness solutions, the core business of the Group, which drove a corresponding increase in cost of sales.

GROSS PROFIT AND GROSS PROFIT MARGIN

Based on the above, the overall gross profit for the six months ended June 30, 2025 and 2026 amounted to approximately RMB64.0 million and approximately RMB85.4 million, respectively, with overall gross profit margin of 22.0% and 26.8%, respectively, in the same periods. The overall gross profit margin increased during the Reporting Period, which was benefitted from the rapid development of the digital healthcare and wellness solutions business.

The Group's gross profit margin for sale of pharmaceutical and healthcare products increased from 1.3% for the six months ended June 30, 2025 to 1.8% for the six months ended June 30, 2026. The overall gross profit margin for sale of pharmaceutical and healthcare products remained at a low level, primarily due to certain business operations involving large-volume transactions with business customers, where competitive pricing is critical for securing orders and represents a strategic choice made by the Company at this specific stage.

The Group's gross profit margin for digital healthcare and wellness solutions increased from 77.4% for the six months ended June 30, 2025 to 80.7% for the six months ended June 30, 2026. Improvement in efficiency drove an increase in the gross profit margin of digital healthcare and wellness solutions, which remained at a relatively high level overall.

SELLING AND MARKETING EXPENSES

The Group's selling and marketing expenses increased by 3.9% from approximately RMB35.4 million for the six months ended June 30, 2025 to approximately RMB36.8 million for the six months ended June 30, 2026, which was mainly attributable to the continuous increase in investment to expand medical resources.

ADMINISTRATIVE EXPENSES

The Group's administrative expenses decreased by 1.2% from approximately RMB27.5 million for the six months ended June 30, 2025 to approximately RMB27.2 million for the six months ended June 30, 2026. The change during the period was relatively small.

RESEARCH AND DEVELOPMENT EXPENSES

The Group's research and development expenses decreased by 11.5% from approximately RMB17.5 million for the six months ended June 30, 2025 to approximately RMB15.4 million for the six months ended June 30, 2026. This was primarily attributable to a reduction in employee benefit expenses of approximately RMB3.5 million, including a decrease of approximately RMB0.2 million in share-based payment expenses, reflecting the enhanced efficiency of the research and development team through the application of AI capabilities.

OTHER INCOME

The Group's other income decreased by 86.6% from approximately RMB2.5 million for the six months ended June 30, 2025 to approximately RMB0.3 million for the six months ended June 30, 2026. This was primarily attributable to a decrease of approximately RMB2.2 million in value-added tax refunds related to the software business.

OTHER LOSSES, NET

For the six months ended June 30, 2026, the Group recorded net other loss of approximately RMB0.2 million, whereas for the six months ended June 30, 2025, the Group recorded net other loss of approximately RMB0.5 million. This was primarily due to the impact of the early termination of an office lease in the first half of 2025, which resulted in a net loss of RMB0.5 million, whereas there was no early termination of office leases during the Reporting Period.

FINANCE COSTS, NET

For the six months ended June 30, 2025 and 2026, the Group recorded net finance costs of approximately RMB1.2 million and approximately RMB4.0 million, respectively, which was primarily due to the net effect of the following: (i) an increase in interest expenses on bank borrowings of approximately RMB2.5 million due to new bank borrowings during the Reporting Period; and (ii) an increase in interest income of approximately RMB1.1 million resulting from an increase in bank deposits, which was offset by a decrease in interest income from related parties of approximately RMB1.6 million, resulting in a decrease in total interest income of approximately RMB0.5 million.

INCOME TAX CREDIT/(EXPENSE)

For the six months ended June 30, 2025 and 2026, we incurred income tax expense of approximately RMB0.4 million and income tax credit of approximately RMB0.1 million, respectively, primarily due to the offset against current income tax expense resulting from the annual tax settlement for 2025 conducted during the first half of 2026.

PROFIT/(LOSS) FOR THE PERIOD

As a result of the foregoing, we recorded loss for the period of approximately RMB19.6 million and profit for the period of approximately RMB1.7 million for the six months ended June 30, 2025 and 2026, respectively.

ADJUSTED NET PROFIT/(LOSS) (NON-IFRS MEASURE)

To supplement our consolidated financial statements which are presented in accordance with International Financial Reporting Standards ("**IFRS**"), we also use adjusted net profit/(loss) (as defined below) as an additional financial measure, which is not required by, or presented in accordance with IFRS. We believe that the presentation of this non-IFRS measure facilitates comparisons of operating performance from period to period and company to company by eliminating potential impact of items such as certain non-cash, non-recurring or non-operating items. We believe that this measure provides useful information to investors in understanding and evaluating the Group's consolidated results of operations in the same manner as it helps our management. However, the use of this non-IFRS measure has limitations as an analytical tool, and should not be considered in isolation from, or as a substitute for analysis of, our results of operations or financial conditions as reported under IFRS. In addition, this non-IFRS financial measure may be defined differently from similar terms used by other companies.

We define "adjusted net profit/(loss) (non-IFRS measure)" as profit/(loss) for the period and adding back (1) share-based compensation expenses and (2) listing expenses. Among the others, share-based compensation expenses are non-cash expenses arising from vesting share options to selected employees and transferring shares from our Shareholders to employees and other parties.

For the six months ended June 30, 2025 and 2026, we recorded an adjusted net loss (non-IFRS measure) of approximately RMB5.1 million and an adjusted net profit (non-IFRS measure) of approximately RMB5.5 million, respectively.

The following table sets forth the reconciliations of our non-IFRS financial measure for the six months ended June 30, 2025 and 2026 to the nearest measure prepared in accordance with IFRS:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	Unaudited	Unaudited
Profit/(loss) for the period	**1,676**	(19,625)
Add:		
Share-based compensation related items	**3,776**	9,936
Listing expenses	**—**	4,628
Adjusted net profit/(loss) (non-IFRS measure)	**5,452**	(5,061)
Adjusted net profit/(loss) margin (non-IFRS measure) (%)	**1.7**	(1.7)

LIQUIDITY AND CAPITAL RESOURCE

For the six months ended June 30, 2026, we funded our cash requirements principally from the cash generated from our operating activities, bank loans and net proceeds from the Global Offering. We had cash and cash equivalents of approximately RMB398.8 million and approximately RMB427.0 million as of December 31, 2025 and June 30, 2026, respectively. Looking forward, the Group will closely monitor the utilization of cash and bank loans, and evaluate loan renewal options upon maturity from time to time based on actual business needs, so as to maintain stable liquidity to support the daily operation of the Company.

The following table sets forth our cash flows for the periods indicated:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	Unaudited	Unaudited
Net cash used in operating activities	**(53,030)**	(5,381)
Net cash (used in)/generated from investing activities	**(12,028)**	1,605
Net cash generated from financing activities	**93,223**	12,286
Net increase in cash and cash equivalents	**28,165**	8,510
Cash and cash equivalents at the beginning of the period	**398,806**	58,266
Cash and cash equivalents at the end of the period	**426,971**	66,776

NET CASH USED IN OPERATING ACTIVITIES

For the six months ended June 30, 2026, our net cash used in operating activities was approximately RMB53.0 million, which was primarily attributable to the payment of various trade and other payables related to our business operations amounting to approximately RMB58.0 million.

NET CASH USED IN INVESTING ACTIVITIES

For the six months ended June 30, 2026, our net cash used in investing activities was approximately RMB12.0 million, which was primarily attributable to the net effect of the following: (i) payments of RMB18.2 million for investments in unlisted entities; (ii) payments of approximately RMB3.2 million for the purchase of vehicles and equipment; and (iii) a decrease in restricted funds of approximately RMB9.4 million.

NET CASH GENERATED FROM FINANCING ACTIVITIES

For the six months ended June 30, 2026, our net cash generated from financing activities was approximately RMB93.2 million, which was primarily attributable to the proceeds from bank borrowings of RMB158.8 million, partially offset by the repayment of principal and interest of bank borrowings of approximately RMB63.8 million.

Looking ahead, we believe that we will be able to satisfy our liquidity requirements by comprehensively utilizing cash generated from operating activities, external borrowings, net proceeds from the Global Offering, and other funds raised from the capital markets from time to time.

SIGNIFICANT INVESTMENTS

The Group did not make or hold any significant investments (including any investment in an investee company with a value of 5% or more of the Company's total assets as at June 30, 2026) during the six months ended June 30, 2026.

MATERIAL ACQUISITIONS AND DISPOSALS

For the six months ended June 30, 2026, the Group did not have any material acquisitions or disposals of subsidiaries, consolidated affiliated entities or associates.

PLEDGE OF ASSETS

As at June 30, 2026, the Group had no pledged assets.

GEARING RATIO

The Group monitors capital on the basis of the gearing ratio, which is calculated by dividing liabilities excluding financial instruments issued to investors by total assets. As of June 30, 2026, the gearing ratio was 72.6%, as compared with 69.2% as of December 31, 2025. The increase was primarily due to the increase of bank loans.

FOREIGN EXCHANGE EXPOSURE

During the six months ended June 30, 2026, the Group mainly operated in mainland China with most of the transactions settled in RMB. The functional currencies of the Company and the subsidiaries and consolidated affiliated entities operating in China are HKD and RMB, respectively. The management of the Company considers that the business has no significant financial assets or liabilities denominated in currencies other than the respective functional currencies of the group entities, except that the Company's proceeds are denominated in HKD, whereas the Group's interim financial statements are presented in RMB. Therefore, fluctuations in the exchange rate of HKD against RMB will affect the RMB translation amount of such funds. During the Reporting Period, due to the depreciation of HKD, the Group recognized currency translation differences in respect of such HKD-denominated proceeds when preparing the interim financial statements. The Company has closely monitored foreign exchange risk exposure and considered taking appropriate hedging measures in a timely manner to manage and mitigate the potential impact of exchange rate fluctuations on the Group's financial performance.

CREDIT RISK

For the six months ended June 30, 2026, the management of the Company considered that the Group was not subject to material credit risk.

FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

As of June 30, 2026, the Group had no specific future plans for material investments or capital assets.

CONTINGENT LIABILITIES

As at June 30, 2026, the Group did not have any material contingent liabilities.

EMPLOYEES AND REMUNERATION

As at June 30, 2026, the Group had a total of 464 employees. The following table sets forth the total number of employees by function as at June 30, 2026:

Function	Number of employees	Percentage of total number of employees
Research and development	85	18.32%
Business operation	108	23.28%
Sales and marketing	109	23.49%
Customer service and technical support	60	12.93%
Management and administrative	78	16.81%
Product management	24	5.17%
Total	**464**	**100.00%**

We are committed to establishing a competitive and fair remuneration system. In order to effectively motivate our staff, we continually refine our remuneration and incentive policies through market research. We conduct performance evaluations for our employees monthly to provide feedback on their performance. Compensation for our staff typically consists of base salary and a performance-based bonus. The Company has also adopted a pre-IPO equity incentive scheme. We also provide selected directors, senior management, and employees with the opportunity to participate in our Pre-IPO Share Option Scheme, aligning our interests with theirs. To enhance and maintain the knowledge and skills of our workforce, we provide regular and specialized training tailored to the needs of employees in different positions. This includes orientation programs for new hires and technical training for existing staff. In addition, we also provide external training opportunities for members of our management team. For the six months ended June 30, 2026, the Group incurred total staff related cost of approximately RMB65.3 million, as compared to approximately RMB66.5 million for the six months ended June 30, 2025 (including share-based payment expenses).

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

		Unaudited	
		Six months ended June 30,	
	Note	**2026**	2025
		RMB'000	*RMB'000*
Revenue	*3*	**318,750**	290,664
Cost of sales and services	*4*	**(233,378)**	(226,628)
Gross profit		**85,372**	64,036
Selling and marketing expenses	*4*	**(36,776)**	(35,391)
Research and development expenses	*4*	**(15,442)**	(17,456)
Administrative expenses	*4*	**(27,186)**	(27,520)
Net provision of impairment losses on financial assets		**(591)**	(3,686)
Other income		**332**	2,475
Other losses, net		**(175)**	(470)
Operating profit/(loss)		**5,534**	(18,012)
Finance income		**1,116**	1,603
Finance costs		**(5,116)**	(2,781)
Finance costs, net		**(4,000)**	(1,178)
Profit/(loss) before income tax		**1,534**	(19,190)
Income tax credit/(expense)	*5*	**142**	(435)
Profit/(loss) for the period		**1,676**	(19,625)
Other comprehensive income:		**(5,802)**	—
Items that may subsequently reclassified to profit or loss			
Currency translation differences		**(5,802)**	—
Total comprehensive loss		**(4,126)**	(19,625)

	Note	Unaudited Six months ended June 30, **2026** ***RMB'000***	 2025 *RMB'000*
Profit/(loss) for the period attributable to:			
Owners of the Company		**2,137**	(19,115)
Non-controlling interests		**(461)**	(510)
		1,676	(19,625)
Total comprehensive loss attributable to:			
Owners of the Company		**(3,665)**	(19,115)
Non-controlling interests		**(461)**	(510)
		(4,126)	(19,625)
Earnings/(losses) per share for profit/(loss) attributable to owners of the Company *(expressed in RMB Yuan)*			
Basic	*6*	**0.007**	(0.065)
Diluted	*6*	**0.006**	(0.065)

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	Note	**Unaudited As at June 30, 2026** *RMB'000*	Audited As at December 31, 2025 *RMB'000*
ASSETS			
Non-current assets			
Property and equipment		**5,051**	2,793
Right-of-use assets		**5,846**	6,962
Intangible assets		**1,114**	1,352
Prepayments, deposits and other receivables		**29**	2,353
Financial assets at fair value through profit or loss		**32,800**	14,600
Restricted cash		**168**	168
Deferred income tax assets		**6,150**	6,116
		51,158	34,344
Current assets			
Inventories		**1,437**	20,056
Trade receivables	*7*	**265,668**	203,887
Prepayments, deposits and other receivables		**96,721**	83,291
Restricted cash		**10,182**	19,543
Cash and cash equivalents		**426,971**	398,806
		800,979	725,583
Total assets		**852,137**	759,927
EQUITY			
Equity attributable to owners of the Company			
Share capital		**4**	4
Share premium		**935,504**	935,504
Other reserves		**338,898**	340,924
Accumulated losses		**(1,035,267)**	(1,037,404)
		239,139	239,028
Non-controlling interests		**(5,375)**	(4,914)
Total equity		**233,764**	234,114

	Note	Unaudited As at June 30, 2026 *RMB'000*	Audited As at December 31, 2025 *RMB'000*
LIABILITIES			
Non-current liabilities			
Lease liabilities		**1,324**	3,533
Borrowings		**20,000**	2,910
Contract liabilities		**5,227**	2,644
		26,551	9,087
Current liabilities			
Lease liabilities		**5,717**	5,311
Trade payables	*8*	**133,692**	120,579
Borrowings		**320,870**	238,110
Contract liabilities		**48,224**	55,580
Accruals and other payables		**83,311**	96,613
Current income tax liabilities		**8**	533
		591,822	516,726
Net current assets		**209,157**	208,857
Total liabilities		**618,373**	525,813
Total equity and liabilities		**852,137**	759,927

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

1. GENERAL INFORMATION

1.1. General information

160 Health International Limited (the "**Company**") was incorporated in the Cayman Islands on January 31, 2022 as an exempted company with limited liability under the Companies Act (Cap. 22, Law 3 of 1961 as consolidated and revised) of the Cayman Islands. The address of the Company's registered office is 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY-1002, Cayman Islands. The Company's shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited since September 17, 2025.

The Company is an investment holding company. The Company and its subsidiaries (collectively, the "**Group**") are principally engaged in the provision of the following goods and services: (i) sales of pharmaceutical and healthcare products; (ii) provision of digital healthcare and wellness solutions in the People's Republic of China (the "**PRC**").

The ultimate holding company of the Company is LNZ Management Limited, a company incorporated in the British Virgin Islands, which is controlled by Mr. Luo Ningzheng ("**Mr. Luo**"), the founder and the ultimate controlling shareholder (the "**Controlling Shareholder**") of the Group.

This condensed consolidated interim financial report for the six months ended June 30, 2026 (the "**Interim Financial Information**") is presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand (RMB'000) except when otherwise indicated. This Interim Financial Information for the six months ended June 30, 2026 has been approved for issue by the board of directors (the "**Board**") of the Company on August 28, 2026.

2. BASIS OF PREPARATION

This note provides a list of material accounting policies adopted in the preparation of the consolidated financial statements. These policies have been consistently applied to all the periods presented, unless otherwise stated.

The consolidated financial statements of the Group have been prepared in accordance with IFRS Accounting Standards and interpretations issued by the IFRS Interpretations Committee ("**IFRS IC**") applicable to companies reporting under IFRS. The consolidated financial statements comply with IFRS as issued by the International Accounting Standards Board ("**IASB**") and the disclosure requirements of the Hong Kong Companies Ordinance Cap. 622.

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended December 31, 2025, except for the adoption of the following amended International Accounting Standards and IFRS for the first time for the current period's financial information.

2.1. Amended standards adopted by the Group

The Group has adopted the following amendments to existing standards which have been adopted by the Group for the first time for the financial year beginning on January 1, 2026:

- Amendment to IFRS 9 and IFRS 7 — Classification and Measurement of Financial Instruments
- Amendment to IFRS Accounting Standards — Annual improvements to IFRS Accounting Standards — Volume 11
- Amendment to IFRS 9 and IFRS 7 — Contracts Referencing Nature-dependent Electricity

These amendments to existing standards did not result in significant impact on the Group's financial position and results of operation.

2.2. New standards and amendments to existing standards not yet adopted

Standards and amendments to existing standards that have been issued but not yet effective on January 1, 2026 and not been early adopted by the Group as of June 30, 2026 are as follows:

		Effective for annual periods beginning on or after
Amendment to IAS 21	Translation to a Hyperinflationary Presentation Currency	January 1, 2027
IFRS 18	Presentation and Disclosure in Financial Statements	January 1, 2027
IFRS 19	Subsidiaries without Public Accountability: Disclosures	January 1, 2027
Amendment to IAS 28	Fair Value Option for Investments in Associates and Joint Ventures	January 1, 2027 (effective concurrently with IFRS 18)
IFRS 20	Regulatory Assets and Regulatory Liabilities	January 1, 2029
Amendments to IFRS10 and IAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined

The Group will adopt the above new standards and amendments to existing standards as and when they become effective. Management has performed preliminary assessment and does not anticipate any significant impact on the Group's financial position and results of operations upon adopting these standards and amendments to the existing IFRSs.

3. REVENUE AND SEGMENT INFORMATION

3.1. An analysis of the Group's revenue is as follows:

	Unaudited Six months ended June 30, **2026** ***RMB'000***	2025 *RMB'000*
Revenue from contracts with customers:		
— Sales of pharmaceutical and healthcare products	**217,637**	211,405
— Provision of digital healthcare and wellness solutions	**101,113**	79,259
Total	**318,750**	290,664

The timing of revenue recognition of the Group's revenue is as follows:

	Unaudited Six months ended June 30, **2026** ***RMB'000***	2025 *RMB'000*
At a point in time	**251,790**	245,739
Over time	**66,960**	44,925
Total	**318,750**	290,664

3.2. Segment information

The Group is principally engaged in sales of pharmaceutical and healthcare products, as well as provision of digital healthcare and wellness solutions and related services.

The chief operating decision maker ("**CODM**") has been identified as the executive directors, who reviews the Group's internal reporting in order to assess performance and allocate resources. The CODM assesses the performance of the Group's business activities as a whole on a regular basis and considers that the Group has only one reportable segment. Accordingly, no segment information is presented.

The Company is domiciled in the Cayman Islands while the Group operates its business in the PRC and earns all of the revenue from external customers in the PRC. Substantially all of the Group's non-current assets are located in the PRC.

4. **EXPENSES BY NATURE**

Expenses included in cost of sales and services, selling and marketing expenses, administrative expenses and research and development expenses are analysed as follows:

	Unaudited	
	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
Cost of inventory sold	**213,549**	208,446
Employee benefit expenses	**65,286**	66,490
Technical services fee	**9,010**	9,318
Professional services fee	**6,646**	1,472
Business development and travel expenses	**5,542**	6,067
Marketing and advertisement expenses	**2,921**	924
Depreciation of		
— right-of-use assets	**2,497**	3,273
— property and equipment	**632**	1,103
Platform usage expenses	**849**	274
Storage and logistics fees	**812**	1,020
Amortization of intangible assets	**238**	242
Listing expenses (including reporting accountant service fees)	**—**	4,628
Statutory audit services	**—**	18
Others	**4,802**	3,720
	312,782	306,995

5. **INCOME TAX (CREDIT)/EXPENSE**

	Unaudited	
	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
Current income tax	**(68)**	1,012
Deferred income tax	**(74)**	(577)
Income tax (credit)/expense	**(142)**	435

6. EARNINGS/(LOSSES) PER SHARE

Pursuant to a written resolution of shareholders on September 3, 2025, each ordinary share in issue of the Company was sub-divided into 5 ordinary shares immediately before the completion of the listing (the "**Share Subdivision**"). Following the Share Subdivision, the weighted average number of ordinary shares for the purpose of basic and diluted earnings/(losses) per share ("**earnings/(losses) per share**") for the six months ended June 30, 2026 and 2025 has been retrospectively adjusted.

Treasury shares were excluded from the calculation of earnings/(losses) per share.

(i) Basic earnings/(losses) per share

Basic earnings/(losses) per share are calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the respective periods.

	Unaudited Six months ended June 30,	
	2026	2025
Profit/(loss) attributable to owners of the Company for the period *(RMB'000)*	**2,137**	(19,115)
Weighted average number of ordinary shares in issue *('000)*	**303,719**	293,948
Basic earnings/(losses) per share *(RMB Yuan)*	**0.007**	(0.065)

(ii) Diluted earnings/(losses) per share

The Group has potential dilutive shares during the six months ended June 30, 2026 and 2025, which were the share options granted under the pre-IPO share option scheme of the Company.

The Group was making loss from its operation during the six months ended June 30, 2025, the inclusion of the potential dilutive ordinary shares would therefore be anti-dilutive, thus the dilutive losses per share were the same as the basic losses per share for the corresponding period.

Weighted average number of ordinary shares of the Group in issue for the six months ended June 30, 2026 has been determined based on the number of shares in issue, after considering the effect of Share Subdivision involving 235,158,564 shares and 33,645,500 shares issued relating to initial public offering. For the corresponding period, 14,487,990 potential dilutive ordinary shares were included, and therefore the diluted earnings per share for the corresponding period were RMB0.006.

7. TRADE RECEIVABLES

	Unaudited As at June 30, 2026 *RMB'000*	Audited As at December 31, 2025 *RMB'000*
Trade receivables	**301,499**	239,216
Less: allowance for impairment	**(35,831)**	(35,329)
Trade receivables, net	**265,668**	203,887

The carrying amounts of trade receivables approximate their fair value. The Group's trade receivables are mainly denominated in RMB.

Sales are generally made with prescribed credit terms in the sales contracts, usually 1 to 3 months to settle the receivables.

(i) The aging analysis of the trade receivables based on invoice date is as follows:

	Unaudited As at June 30, 2026 *RMB'000*	Audited As at December 31, 2025 *RMB'000*
Within 90 days	**189,734**	129,452
90 days to one year	**59,409**	42,672
One to two years	**26,183**	39,666
Two to three years	**13,615**	14,686
Over three years	**12,558**	12,740
	301,499	239,216

8. TRADE PAYABLES

Aging analysis of the trade payables as at June 30, 2026 and December 31, 2025 based on invoice date is as follows:

	Unaudited As at June 30, 2026 *RMB'000*	Audited As at December 31, 2025 *RMB'000*
Trade payables	**133,692**	120,579
Analysis by aging		
Within 90 days	**88,542**	87,998
90 days to one year	**21,236**	13,514
Over one year	**23,914**	19,067
	133,692	120,579

9. DIVIDEND

No dividends were paid or declared by the Company or any companies now comprising the Group during the six months ended June 30, 2026 and 2025.

OTHER INFORMATION

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the Corporate Governance Code (the "**CG Code**") as set out in Appendix C1 to the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") as its own code of corporate governance. Save as disclosed below, during the Reporting Period and up to the date of this announcement, the Company complied with all applicable code provisions under the CG Code and adopted most of the best practices set out therein.

Pursuant to code provision C.2.1 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Mr. Luo Ningzheng is currently serving as the chairman of the Board as well as the chief executive officer of the Company. As Mr. Luo is the founder of the Group and has been managing the Group's business and overall strategic planning since its establishment, the Directors consider that vesting the roles of chairman and chief executive officer in Mr. Luo is beneficial to the business prospects and management of the Group by ensuring consistent leadership within the Group. Taking into account all the corporate governance measures that we are going to implement upon Listing, the Board considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively. Accordingly, the Company had not segregated the roles of its chairman and chief executive officer. The Board will continue to review and consider splitting the roles of chairman of the Board and the chief executive officer at an appropriate time if necessary, taking into account the circumstances of the Group as a whole.

On August 14, 2026, Ms. Sun Meng ("**Ms. Sun**") has resigned as a non-executive Director and a member of the nomination committee under the Board. Following Ms. Sun's resignation, the Company has a single-gender Board, which does not comply with Rule 13.92(2) of the Listing Rules. The Company also failed to comply with the requirements under code provision B.3.5 of the CG Code, which states that the Company should appoint at least one member of a different gender from the existing members to the nomination committee. As at the date of this announcement, the Company has not yet appointed a new Director. The Company will use its best endeavors to identify a suitable female candidate for appointment as a Director, and will appoint a suitable female candidate as a Director within three months from the date of Ms. Sun's resignation to improve the structure of the Board and the nomination committee, and to comply with the requirements of Rule 13.92(2) of the Listing Rules and code provision B.3.5 of the CG Code as soon as possible.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding directors' securities transactions.

Having made specific enquiry with all Directors, they have confirmed that they had complied with the required standards set out in the Model Code for the six months ended June 30, 2026.

INTERIM DIVIDEND

The Board does not recommend the payment of any interim dividend for the six months ended June 30, 2026.

AUDIT COMMITTEE

The Company has established the audit committee (the "**Audit Committee**") with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the CG Code set out in Appendix C1 to the Listing Rules. The Audit Committee members consist of two independent non-executive Directors, namely Mr. Wang Huan (chairman) and Dr. Xu Weiguo, and one non-executive Director, namely Mr. Liu Haibin. Mr. Wang Huan, as the chairman of the Audit Committee, possesses appropriate professional qualifications. The primary duties of the Audit Committee are to review and oversee the Group's financial reporting procedures, risk management and internal control.

The Audit Committee has reviewed the accounting principles and policies adopted by the Group and discussed the Group's financial reporting matters with the management. The Audit Committee has reviewed the condensed interim results of the Group for the six months ended June 30, 2026.

The unaudited interim results of the Group for the six months ended June 30, 2026 have not been audited nor reviewed by the Company's auditors.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

For the six months ended June 30, 2026, the Company did not hold any treasury shares (as defined in the Listing Rules).

For the six months ended June 30, 2026, neither the Company nor any of its subsidiaries or consolidated affiliated entities had purchased, sold, or redeemed any of the Company's listed securities (including the sale of any treasury shares).

USE OF PROCEEDS FROM GLOBAL OFFERING

The Shares were listed on the Stock Exchange on September 17, 2025. The net proceeds from the Global Offering received by the Company (after deducting underwriting commissions and related costs and expenses) amounted to approximately HK$308.5 million (the "**Net Proceeds**"). The Company intends to utilize the Net Proceeds in the manner and proportions as disclosed in the Prospectus.

For the six months ended June 30, 2026, there has been no change to the proposed use and expected timeline of the Net Proceeds as previously disclosed in the section headed "Future Plans and Use of Proceeds" of the Prospectus. The table below sets out a summary of the utilization of the Net Proceeds for the six months ended June 30, 2026:

Intended use of Net Proceeds	Approximate percentage of Net Proceeds	Planned amount of Net Proceeds to be used *(approximately HK$ million)*	Net Proceeds unutilized as at December 31, 2025 *(approximately HK$ million)*	Net Proceeds utilized during the Reporting Period *(approximately HK$ million)*	Net Proceeds unutilized as at June 30, 2026 *(approximately HK$ million)*	Expected timeline for full utilization of the remaining Net Proceeds[1]
Further broaden medical resource coverage and boost traffic to our platform	40%	123.4	120.4	4.9	115.5	By December 31, 2030
Strengthen our research and development capabilities	30%	92.4	90.3	6.8	83.5	By December 31, 2030
Diversify our product and service offerings and explore value-added services	10%	30.9	30.6	0.2	30.4	By December 31, 2030
Selectively pursue strategic cooperation and acquisitions	10%	30.9	14.9	14.9	—	Not applicable
Working capital and general corporate purpose	10%	30.9	30.9	30.9	—	Not applicable
Total[2]	**100%**	**308.5**	**287.1**	**57.7**	**229.4**	

Notes:

(1) The expected timeline for full utilization of the remaining Net Proceeds as set out in the table above is based on the best estimate of the Group with respect to future market conditions, which may be subject to change depending on the development of current and future market conditions.

(2) Due to rounding, the total figures may not be equal to the sum of the individual amounts.

As at June 30, 2026, the remaining Net Proceeds of approximately HK$229.4 million were deposited in licensed commercial bank(s).

EVENTS AFTER THE REPORTING PERIOD

Save as disclosed in the section headed "Compliance with the Corporate Governance Code" above, after the Reporting Period and as at the date of this announcement, there is no significant event.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.91160.com). The interim report of the Company for the six months ended June 30, 2026 will be published electronically on the respective websites of the Stock Exchange and the Company in accordance with the requirements under the Listing Rules.

By order of the Board
160 Health International Limited
Mr. LUO Ningzheng
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, August 28, 2026

As of the date of this announcement, the Board comprises (i) Mr. LUO Ningzheng, Mr. JI Cuilin, Mr. HUANG Lang and Mr. WANG Lifa as executive Directors; (ii) Mr. LIU Haibin as non-executive Director; and (iii) Mr. WANG Huan, Dr. XU Weiguo and Dr. FAN Ming as independent non-executive Directors.